AsthmaFinnATOPYNCT06330974
Allergy, Asthma, and Atopic Eczema in Finland
An observational study of Asthma and Asthma in Children, run by Tampere University at 1 site in Finland.
Trial summary
The summary is available at --> https://www.finnatopy.fi/summary Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Asthma, Asthma in Children, Allergy
- How many people
- 1,200,000 participants
- Where
- 1 siteFinland
- Study dates
- 1 Dec 2026to Dec 2034
- How long will I take part?
- 7 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: https://www.finnatopy.fi/methods
Inclusion/Exclusion Criteria ---> https://www.finnatopy.fi/methods
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden
The summary is available at --> https://www.finnatopy.fi/summary
Read the detailed description
Aims and objectives ---> https://www.finnatopy.fi/aims-and-objectives Methods ---> https://www.finnatopy.fi/methods
- Conditions
- Asthma, Asthma in Children, Allergy, Rhinitis, Allergic, Atopic Dermatitis, Allergen Immunotherapy
- Being tested
- No intervention, No Intervention: Observational Cohort
- Medical subject headings
- Asthma, Hypersensitivity, Rhinitis, Allergic, Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
No Intervention: Observational CohortOther
No intervention
| Study group | Role | What they receive |
|---|---|---|
| Atopic | Patientes with any atopic condition (g.e., asthma, atopic dermatitis, IgE-mediateid allergy) Receives: Other: No intervention; Other: No Intervention: Observational Cohort | |
| Control group - migrane | Patients with migrane Receives: Other: No intervention; Other: No Intervention: Observational Cohort | |
| Control group - celiac disease | Patients with celiac disease Receives: Other: No intervention; Other: No Intervention: Observational Cohort | |
| Control group - UTI | Patients with urinary tract infection Receives: Other: No intervention; Other: No Intervention: Observational Cohort | |
| Control group - LRTI | Patients with lower respiratory tract infection Receives: Other: No intervention; Other: No Intervention: Observational Cohort | |
| Control group - bronchitis | Patients with acute bronchitis Receives: Other: No intervention; Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Epidemiology of atopic diseases and allergic sensitization profiles in Finland
Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis
Measured: 7 years
Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland
Morbidity, sick leaves, medication use, costs and expences
Measured: 7 years
Evaluate and improve the current use of diagnostic tests for atopic diseases
Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.
Measured: 7 years
Use and effectiveness of allergen immunotherapy in real world setting
Real world evidence data using specific cohorts
Measured: 7 years
Direct and indirect costs related to atopic diseases and comorbidities
All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.
Measured: 7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2024
- Study start1 Dec 2026 (estimated)
- Primary completionDec 2032 (estimated)
- Study completionDec 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,200,000 participants (estimated)
- Target duration
- 7 Years
Sponsor and investigators
- Lead sponsor
- Tampere University
- Sponsor type
- University, hospital or other
- Collaborators
- Professor Lauri Lehtimäki, Professor Mika Mäkelä, Professor Sanna Toppila-Salmi, Professor Ilkka Junttila
- Responsible party
- Principal investigator, Peter Csonka, Tampere University
- Investigators
- Péter Csonka, Principal investigator, Tampere University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06330974
- Sponsor's protocol ID
- FinnATOPY
- Acronym
- FinnATOPY
- Status last verified
- Oct 2026
- First submitted
- 12 Mar 2024
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden
- ClinicalTrials.gov ID
- NCT06330974
- Acronym / sponsor ID
- FinnATOPY / FinnATOPY
- Conditions
- Asthma, Asthma in Children, Allergy, Rhinitis, Allergic, Atopic Dermatitis, Allergen Immunotherapy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,200,000 participants (estimated)
- Lead sponsor
- Tampere UniversityUniversity, hospital or other
- Collaborators
- Professor Lauri Lehtimäki, Professor Mika Mäkelä, Professor Sanna Toppila-Salmi, Professor Ilkka Junttila
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- Dec 2032 (estimated)
- Study completion
- Dec 2034 (estimated)
- First posted
- 26 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The summary is available at --> https://www.finnatopy.fi/summary
Detailed description
Aims and objectives ---> https://www.finnatopy.fi/aims-and-objectives Methods ---> https://www.finnatopy.fi/methods
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 7 Years
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Atopic | – | Other: No intervention, Other: No Intervention: Observational CohortPatientes with any atopic condition (g.e., asthma, atopic dermatitis, IgE-mediateid allergy) |
| Control group - migrane | – | Other: No intervention, Other: No Intervention: Observational CohortPatients with migrane |
| Control group - celiac disease | – | Other: No intervention, Other: No Intervention: Observational CohortPatients with celiac disease |
| Control group - UTI | – | Other: No intervention, Other: No Intervention: Observational CohortPatients with urinary tract infection |
| Control group - LRTI | – | Other: No intervention, Other: No Intervention: Observational CohortPatients with lower respiratory tract infection |
| Control group - bronchitis | – | Other: No intervention, Other: No Intervention: Observational CohortPatients with acute bronchitis |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- https://www.finnatopy.fi/methods
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo intervention | Other | Atopic, Control group - LRTI, Control group - UTI, Control group - bronchitis, Control group - celiac disease, Control group - migrane |
| No Intervention: Observational CohortNo intervention | Other | Atopic, Control group - LRTI, Control group - UTI, Control group - bronchitis, Control group - celiac disease, Control group - migrane |
Primary outcome
Epidemiology of atopic diseases and allergic sensitization profiles in Finland
Time frame: 7 years
Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis
Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland
Time frame: 7 years
Morbidity, sick leaves, medication use, costs and expences
Evaluate and improve the current use of diagnostic tests for atopic diseases
Time frame: 7 years
Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.
Use and effectiveness of allergen immunotherapy in real world setting
Time frame: 7 years
Real world evidence data using specific cohorts
Direct and indirect costs related to atopic diseases and comorbidities
Time frame: 7 years
All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Asthma
Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Asthma, Atherosclerosis
Not yet recruitingObservational study
Prevelance of Broncial Asthma and Allergic Rhinitis in Children With Nephrotic Syndrim
Bronchial Asthma, Allergic Rhinitis
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Péter Csonka principal investigator
Tampere University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma and Asthma in Children, run by Tampere University at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Péter Csonka, MD, PhD (+358503661103, peter.csonka@tuni.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Epidemiology of atopic diseases and allergic sensitization profiles in Finland (time frame: 7 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.